Drug Profile
IFX 3
Latest Information Update: 03 Mar 2021
Price :
$50
*
At a glance
- Originator InflaRx
- Class Monoclonal antibodies
- Mechanism of Action Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 03 Mar 2021 Discontinued - Preclinical for Inflammation in Germany (unspecified route)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Inflammation in Germany
- 03 Mar 2016 Preclinical trials in Inflammation in Germany (unspecified route) before March 2016